Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCELL VACCINE TRIAL: hAd5-S-Fusion+N-ETSD for COVID-19
NCT06022224Phase 3Terminated
- Sponsor
- ImmunityBio, Inc.
- Start
- Dec 2020
- Primary completion
- Jun 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing hAd5-S-Fusion+N-ETSD with Placebo (2 arms). Primary endpoint: Number of Participants With Adverse Events up to 7 months. Started Dec 2020; status: terminated.
02
Drugs
hAd5-S-Fusion + N-ETSD
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06022224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06022224.